Susanne Kohout, the Country President and Managing Director of our EuroNeurotrophin Partner Organisation, Novartis (Hellas) S.A.C.I. in Greece held an interview with Fortune Greece on Novartis’ mission to help people live longer and better.
In the interview, Susanne Kohout tells us about her background and the development of the organisation and its strong position in the global market and how it got there. She also raises the concerns and challenges the COVID-19 pandemic has brought to Greece and the company itself and how they are handling this situation.
The full article is available to read online on fortunegreece.com
Novartis is ranked amongst one of the companies most heavily investing in R&D globally and we are happy to have them involved in the EuroNeurotrophin Project.
Alessia Latorrata (ESR2) presented the research from her individual research project during the Synthesis in Drug Discovery and Development Virtual Symposium, 22.-23. March. Her poster titled ”Synthesis of new DHEA 17-spyro-cyclopropyl derivatives with Neurotrophic, Neuroprotective and Anti-Inflammatory activity” was presented during the virtual poster sessions to chemists from industry and academia, including synthetic, medicinal and process chemists.
At the Journées de l'Ecole Doctorale Normande de Chimie 2020, ESR6 Mirjana Antonijević won with her presentation the best oral communication prize. The meeting was held online on the 27/28. November 2020.
JEDNC is an annual meeting organized by PhD students and for PhD students of the Normandy University which includes three universities: the University of Rouen, the University of Le Havre and the University of Caen. This congress enables PhD students to share their research work, in different fields and with professionals from academia and industry.
Mirjana Antonijević won with her presentation about "Multi-target neurotrophin receptors ligands, an emerging strategy in the treatment of neurodegenerative diseases".
Award-winning Sheffield neuroscientists honoured at Buckingham Palace reception
The prize awarded to the University of Sheffield recognises the work that the Sheffield Institute for Translational Neuroscience (SITraN) at the University does to improve patient outcomes for people living with some of the most devastating neurodegenerative diseases.
Achievements highlighted by the award included:
The prize is unique in the UK honours system, as it is only bestowed upon a UK college or university which demonstrates new and unique innovative approaches to its research.
Professor Dame Pamela Shaw, Director of SITraN and the NIHR Sheffield Biomedical Research Centre, said: “This prize recognises the University of Sheffield as a centre for excellence in neuroscience research and teaching, where our researchers are making lifechanging discoveries and progress in treating some of the most devastating neurological diseases, making a real difference to patients’ lives.
“As well as making life-changing discoveries today, we are also nurturing the next generation of talented neuroscience students, whose research will lead to pioneering treatments for those living with neurological diseases in the future. This includes the Euroneurotrophin PhD Studentship programme with colleagues from several European countries”
“We hope this award will help inspire confidence in patients and their families, research
partners and donors, as we continue to make discoveries that deepen the understanding of
neurological diseases and open up the potential for new treatments and therapies.”
SITraN’s vision is to harness the rapidly emerging, exciting developments in neuroscience to
translate into new treatments and improved quality of life for patients with neurodegenerative disorders such as Parkinson’s Disease, MND, Alzheimer’s Disease, MS and Dementia.
The centre - considered a world-leader in neuroscience research - will celebrate its 10th anniversary this year. Its work forms part of the University of Sheffield’s Neuroscience Institute, which aims to bring academics together from across medicine, science and engineering to translate scientific discoveries from the lab into pioneering new treatments.
Sir Damon Buffini, Chairman of the Royal Anniversary Trust, said: “It has been fantastic to celebrate the 13th Round of Prize-winners at Buckingham Palace alongside TRH Prince of Wales and the Duchess of Cornwall. The Royal Anniversary Trust showcased the exceptional, innovative and impactful work of our colleges and universities throughout the UK. We look forward to seeing how the work develops and progresses over the coming years!”
All the ESRs had the great opportunity to attend a two-day workshop on Patenting and Commercialising Novel Biomedical Inventions held by Ventac Partners. Dr. Kostas Alevizopoulos and Dr. Neil Thomas brought the ESRs to the patent world, dealing with drawing up of a business plan, request for a patent and negotiation with investors for funding.